Abstract Number: 862 • 2012 ACR/ARHP Annual Meeting
What Is the Impact of a Transition Program On Adolescents with Juvenile Idiopathic Arthritis and Their Parents ?
Background/Purpose: To date, there is no structured or systematic approach in Belgium for transferring adolescents with juvenile idiopathic arthritis from pediatric rheumatology to an adult…Abstract Number: 863 • 2012 ACR/ARHP Annual Meeting
Employment of a Needs Assessment Survey to Shape a Novel Web-Based Pediatric Rheumatology Curriculum for Primary Care Providers
Background/Purpose: Pediatric rheumatology faces many challenges due to the shortage of board certified physicians in the field and the imbalance in their geographic distribution. This…Abstract Number: 864 • 2012 ACR/ARHP Annual Meeting
Will I Waste Your Time? Delays in Help-Seeking for RA Flares
Background/Purpose: Anecdotal evidence suggests that patients vary in how long they wait before seeking medical help for an RA flare. The aim of this research…Abstract Number: 865 • 2012 ACR/ARHP Annual Meeting
A Methodology for Estimating Disease State Transitions: Repeated Measures Markov Models with Covariate Dependence
Background/Purpose: Many RA patients have variable disease activity over time due to disease flare, reduction in efficacy of current medications and other disease mediating…Abstract Number: 866 • 2012 ACR/ARHP Annual Meeting
Pain Is Associated with Telomere Shortening in Women with Fibromyalgia
Background/Purpose: Telomere length is considered a marker of cellular aging and has been linked to an increased risk for morbidity and mortality. Psychosocial factors associated…Abstract Number: 867 • 2012 ACR/ARHP Annual Meeting
Events That Trigger the Onset of the Fibromyalgia Syndrome (FMS)
Background/Purpose: Triggering events – those that are followed by the onset or rapid increase in FMS symptoms – have a significant impact in some cases. …Abstract Number: 868 • 2012 ACR/ARHP Annual Meeting
Illness Perceptions Among Patients with Different Forms of Vasculitis
Background/Purpose: Patient-held beliefs about their illness are central for understanding patient reactions to specific diseases. This study aimed to compare illness perceptions, defined as the…Abstract Number: 869 • 2012 ACR/ARHP Annual Meeting
Concepts Which Determine Health in a Positive Way Are Important to People with Rheumatoid Arthritis and Are Covered by Some Patient-Reported Outcome Instruments
Background/Purpose: Rheumatoid arthritis is a chronic autoimmune disease that has a major impact on functioning, health and well-being. Concepts which determine health in a positive…Abstract Number: 870 • 2012 ACR/ARHP Annual Meeting
To Love and to Hold: Men Describe Parenting in the Presence of Inflammatory Arthritis
Background/Purpose: Inflammatory arthritis (IA) may limit participation in life roles such as parenting. Surprisingly little research has investigated the impact of IA on parenting tasks…Abstract Number: 871 • 2012 ACR/ARHP Annual Meeting
Depression Predicts Mortality in RA
Background/Purpose: Depression rates are elevated among individuals with rheumatoid arthritis (RA). Studies in cardiovascular disease and among elderly populations have found that depression is…Abstract Number: 872 • 2012 ACR/ARHP Annual Meeting
Monocyte Chemoattractant Protein-1 and Eotaxin Are Associated with Parameters of Cardiac Dysfunction in Juvenile Dermatomyositis
Background/Purpose : Juvenile dermatomyositis (JDM) is a vasculopathic disease affecting not only skeletal muscle and skin, but other organs as well. Previously we have shown…Abstract Number: 833 • 2012 ACR/ARHP Annual Meeting
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study of Intravenous Staphylococcal Protein A in Patients with Active Rheumatoid Arthritis On Methotrexate: Safety, Pharmacokinetics and Efficacy
Background/Purpose: PRTX-100 is highly-purified GMP staphylococcal protein A (SpA) that binds with extremely high affinity to the Vh antibody framework region of Clade Vh3 immunoglobulins. …Abstract Number: 834 • 2012 ACR/ARHP Annual Meeting
Cetrorelix, a Gonadotropin-Releasing Hormone Antagonist, Significantly Reduces Tumour-Necrosis-Factor-Alpha and Demonstrates Efficacy in Patients with Active Rheumatoid Arthritis: A Proof-of-Concept, Double-Blind, Randomised Trial
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is unclear, and treatment options can be improved. Gonadotropin-releasing hormone (GnRH) stimulates immune responses (1) and therefore might…Abstract Number: 835 • 2012 ACR/ARHP Annual Meeting
Low Doses of Ocaratuzumab, a Fc- and Fab-Engineered Anti-CD20 Antibody, Result in Rapid and Sustained Depletion of Circulating B-Cells in Rheumatoid Arthritis Patients
Background/Purpose: B-cell depletion provides therapeutic benefits for patients with rheumatoid arthritis (RA). Ocaratuzumab, previously known as AME-133v, is a Fc- and Fab-engineered, humanized, anti-CD20…Abstract Number: 836 • 2012 ACR/ARHP Annual Meeting
Clinical Responses and Patient Reported Outcomes to NNC0109-0012 (anti-IL-20 mAb) in Rheumatoid Arthritis (RA) Patients Following 12-Weeks Dosing and 13 Weeks Follow up: Results From a Phase 2a Trial
Background/Purpose: NNC0109-0012 (anti-IL-20 mAb) is a novel human monoclonal IgG4 antibody which binds to and neutralizes the activity of IL-20. Data from a phase 1…